Low skeletal muscle is associated with toxicity in patients included in phase I trials

Author： Cousin Sophie   Hollebecque A.   Koscielny S.   Mir O.   Varga A.   Baracos V.   Soria J.   Antoun S.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.32, Iss.2, 2014-04, pp. : 382-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Lower toxicity with targeted anticancer agents in phase I trials

By  

Reactions Weekly, Vol. 1, Iss. 1416, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials

By Yin Guosheng   Zheng Shurong   Xu Jiajing  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 4, 2013-07 ,pp. : 856-870

Taylor & Francis Ltd

Access to resources Recommend Favorite

Adaptive Bayesian Design for Phase I Dose-Finding Trials Using a Joint Model of Response and Toxicity

By Wang Meihua  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 125-144

Taylor & Francis Ltd

Access to resources Recommend Favorite

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

By Ederhy Stephane  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 611-615

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic, Dosimetry and Toxicity Study of 177Lu-EDTMP in Patients: Phase 0/I study

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 71-84

Bentham Science Publishers

Access to resources Recommend Favorite